GLP-1
Selected indexed studies
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. (Front Endocrinol (Lausanne), 2024) [PMID:39114288]
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. (Front Endocrinol (Lausanne), 2021) [PMID:34497589]
- How May GIP Enhance the Therapeutic Efficacy of GLP-1? (Trends Endocrinol Metab, 2020) [PMID:32396843]
_Worker-drafted node — pending editorial review._
Connections
GLP-1 is a risk factor for
Sources
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. (2024) pubmed
- GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. (2021) pubmed
- Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. (2023) pubmed
- Boosting GLP-1 by Natural Products. (2021) pubmed
- GLP-1: Molecular mechanisms and outcomes of a complex signaling system. (2019) pubmed
- GLP-1-based medications: Mechanisms involved in obesity treatment. (2025) pubmed
- GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. (2023) pubmed
- New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. (2023) pubmed
- The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. (2022) pubmed
- Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. (2023) pubmed
- How May GIP Enhance the Therapeutic Efficacy of GLP-1? (2020) pubmed